Host populations, challenges, and commercialization of cryptococcal vaccines
PLOS Pathogens · 09.02.2023 · 19 (2) · e1011115
DOI: 10.1371/journal.ppat.1011115 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 09.02.2023. Verfasst von Maurizio Del Poeta und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, United States of America. Hauptthemen laut MEDLINE: COVID-19, Vaccines, Communicable Diseases, Cryptococcus neoformans. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NIAID NIH HHS, NIH.
Abstract (Originalsprache)
Vaccines are one of the most effective public health tools to prevent and manage infectious diseases. Since the first clinical use of vaccines in the late 18th century, many vaccines have been successfully developed to combat bacterial and viral infections, including the most recent Coronavirus Disease 2019 (COVID-19) pandemic. However, there remains no vaccine that is clinically available to treat or prevent invasive fungal diseases, including cryptococcal meningoencephalitis. This fungal disease is uniformly fatal without treatment and has a global mortality rate of over 70%. Despite a dire need for an effective cryptococcal vaccine, there are many scientific and economic challenges to overcome prior to making it a reality. Here, we discuss some of these challenges as well as steps that the community is taking for commercialization of effective cryptococcal vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, United States of America.
- Division of Infectious Diseases, Stony Brook University, Stony Brook, New York, United States of America.
- Institute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, New York, United States of America.
- Veteran Administration Medical Center, Northport, New York, United States of America.
- Department of Biology, Texas Christian University, Fort Worth, Texas, United States of America.
- Department of Microbiology, University of Georgia, Athens, Georgia, United States of America.
ORCID-Profile: Xiaorong Lin
Förderung
- BLRD VA
- NIAID NIH HHS
- NIH
- the Veterans Affairs (VA) Program
- the Department of Defense
- the Research Career Scientist
Zitieren
APA
Del Poeta, M., Wormley, F. L., & Lin, X. (2023). Host populations, challenges, and commercialization of cryptococcal vaccines. PLOS Pathogens, 19(2), e1011115. https://doi.org/10.1371/journal.ppat.1011115
Vancouver
Del Poeta M, Wormley FL, Lin X. Host populations, challenges, and commercialization of cryptococcal vaccines. PLOS Pathogens. 2023;19(2):e1011115. doi:10.1371/journal.ppat.1011115
BibTeX
@article{DelPoeta2023,
author = {Del Poeta, Maurizio and Wormley, Floyd L and Lin, Xiaorong},
title = {Host populations, challenges, and commercialization of cryptococcal vaccines},
journal = {PLOS Pathogens},
year = {2023},
volume = {19},
number = {2},
pages = {e1011115},
doi = {10.1371/journal.ppat.1011115}
}
EUVIMED